ArticleClinical oral investigations2013
Prognostic value of histamine H1 receptor expression in oral squamous cell carcinoma.
Article in Clinical oral investigations, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Cyclic increase in the histamine receptor H1-ADAM9-Snail/Slug axis as a potential therapeutic target for EMT-mediated progression of oral squamous cell carcinoma.Cell death & disease · 2025Article
- Review
- Review
- Article
- Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets.Biomolecules · 2021Review
- Histamine receptors and cancer pharmacology: an update.British journal of pharmacology · 2020Review
- Histamine HCellular oncology (Dordrecht, Netherlands) · 2017Article
- Cyclin D1 expression in Bowen's disease and cutaneous squamous cell carcinoma.Molecular and clinical oncology · 2014Article
- CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas.Clinical oral investigations · 2014Article
- CognitionMaster: an object-based image analysis framework.Diagnostic pathology · 2013Article
- Molecular and cellular analysis of human histamine receptor subtypes.Trends in pharmacological sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOverexpression of the histamine H1 receptor (H1R) has been described in a variety of tumor models, but experience in oral squamous cell carcinomas (OSCC) is not available. Current adjuvant treatment options for OSCC can be improved by the identification of new targets of therapy. Herein, we evaluated H1R expression in a large patient cohort of OSCC. MATERIALS AND
methodsH1R immunoexpression was evaluated in 191 cases of OSCC and two OSCC cell lines BICR56 and BICR3. Scanned images were digitally analyzed using ImageJ and the immunomembrane plug-in. The combined score of computer-assisted semiquantitative analysis was correlated with manually counted percentages of tumor cells by Kendall's tau (т) correlation coefficient. Disease-free survival times were estimated using the Kaplan-Meier method and were compared by using the log-rank test. Multivariate analyses were performed using the Cox proportional hazards model.
resultsH1R was rarely expressed in OSCC but significantly related with advanced tumor stages (n = 21/191, mean expression 63.5% of cancer cells in positive tumor samples, 95% confidence interval of the mean 53.5 to 73.6%, p = 0.006). Following univariate analysis, patients with H1R expression showed a significant poorer prognosis (p = 0.0004). Multivariate analysis revealed H1R expression as an independent prognostic factor (p = 0.0164). Expression of H1R in cancer cell lines was confirmed by specific staining of OSCC cell lines BICR56 and BICR3.
conclusionThis is the first study focusing on H1R expression showing a significant poorer DFS rate in the H1R+ patient cohort. Based on these data, H1R activation may promote carcinogenesis in OSCC. CLINICAL RELEVANCE: Investigation of H1R regulation and its antagonists shows a clear rationale for future supportive anticancer therapies in OSCCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.